The FDA approved subcutaneous Opdivo for solid tumors, providing a more convenient treatment option that reduces time toxicity and enhances patient accessibility. Subcutaneous administration allows ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with chemotherapy as a first-line treatment for metastatic non–small cell lung ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
The objective of this study is to assess whether the duration and exclusiveness of breastfeeding, and the timing of introduction of solid foods are associated with the subcutaneous fat mass in ...
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback